Immunogenicity and Efficacy of Pneumococcal Conjugate Vaccine (Prevenar13®) in Preventing Acquisition of Carriage of Pneumococcal Vaccine Serotypes in Tanzanian Children With HIV/AIDS.

Citation metadata

Publisher: Frontiers Research Foundation
Document Type: Article
Length: 407 words
Lexile Measure: 1500L

Document controls

Main content

Article Preview :

Author(s): Makenga, Geofrey, Mtove, George, Yin, J. Kevin, Mziray, Abubakary, Bwana, Veneranda M., Kisinza, William, Mjema, Julius, Amos, Ben, Antony, Laura, Shingadia, Delane, Oftadeh, Shahin, Booy, Robert

In every year, up to one million children die due to pneumococcal disease. Children infected with Human Immunodeficiency Virus (HIV) are mostly affected, as they appear to have higher rates of pneumococcal carriage and invasive disease. Successful immunity is dependent on mounting a sufficient immune response to the vaccine. We conducted a double blinded crossover randomised controlled trial to determine the serum antibody response (>4-fold and geometric mean concentration) to pneumococcal vaccine (PCV13) serotypes...

Source Citation

Source Citation   

Gale Document Number: GALE|A674820023